Polypharmacology of N6-(3-Iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential-Reference-Cited by-同舟云学术

Polypharmacology of N6-(3-Iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential

Published:2017-08-28 Issue:17 Volume:60 Page:7459-7475
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yu Jinha,Ahn Seyeon,Kim Hee Jin¹,Lee Moonyoung,Ahn Sungjin,Kim Jungmin,Jin Sun Hee,Lee Eunyoung,Kim Gyudong,Cheong Jae Hoon¹,Jacobson Kenneth A.²^ORCID,Jeong Lak Shin^ORCID,Noh Minsoo^ORCID

Affiliation:

1. Uimyung Research Institute for Neuroscience, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815, Nowon-gu, Seoul 139-742, Republic of Korea

2. Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, United States

Funder

U.S. Department of Health and Human Services

National Research Foundation of Korea

Seoul National University

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00805

Reference81 articles.

1. Network pharmacology: the next paradigm in drug discovery